• Pfizer Inc., of New York, said the FDA granted regular approval for Xalkori (crizotinib) for use in patients with metastatic ALK-positive non-small-cell lung cancer as detected by an FDA-approved test. Xalkori previously gained accelerated approval in August 2011.